The Energy Breakthrough That Could Power the AI Era

(CNSX:MAXX.CN),(CNSX:MAXX),(PinkSheets:MAXXF), This article has been disseminated on behalf of MAX Power Mining and may include a paid advertisement. AUSTIN, Texas, Nov. 10, 2025 (GLOBE NEWSWIRE) — NetworkNewsWire Editorial Coverage: Artificial intelligence (“AI”) isn't just changing technology — it's rewriting the global energy equation. The world's smartest machines now require staggering amounts of electricity, pushing grids […]

The New Gold Rush of the AI Era

(CNSX:ESAU.CN),(OTCQB:ESAUF),(CNSX:ESAU), This article has been disseminated on behalf of ESGold Corp. and may include a paid advertisement. AUSTIN, Texas, Nov. 10, 2025 (GLOBE NEWSWIRE) — NetworkNewsWire Editorial Coverage: Artificial intelligence (“AI”) runs on gold and silver, the same metals found in every chip, data center, and iPhone, yet global reserves and refining capacity are tightening

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

(NASDAQ:PDSB), Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy PDS01ADC reprograms natural killer (NK) cells to possess characteristics that make them more active in killing cancer cells PDS01ADC promotes stem cell-like killer T cells and memory T cells that self-replicate and are therefore capable of potent and long-lasting

Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors

(NASDAQ:AKTX), Data presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting The spliceosome targeting payload, PH1, demonstrates the ability to induce both cancer cell cytotoxicity and activation of anti-tumor immunity through multiple mechanisms Treatment with a Trastuzumab-PH1 ADC monotherapy drove macrophages to polarize into an anti-tumor/inflammatory state and caused expansion of B

Roper Technologies strengthens AI leadership with key executive appointments

(NASDAQ:ROP), SARASOTA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) — Roper Technologies, Inc. (Nasdaq: ROP) today announced the appointments of Shane Luke as Senior Vice President of AI and Edward Raffaele as Vice President of AI Engineering. In these newly created roles, Luke and Raffaele will focus on advancing AI capabilities across Roper's portfolio of market-leading

Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk(R) Hereditary Cancer Test to Support Evolving Clinical Needs

(NASDAQ:MYGN), SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced MyRisk(R) Hereditary Cancer Test–the gold standard in germline testing–has been expanded to include genes referenced in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(R))1 and guidelines from American Society

Vittoria Biotherapeutics Announces Presentation of First-in-Human Interim Phase1 Data for VIPER-101 at ASH2025

PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) — Vittoria Biotherapeutics, Inc., a clinical-stage immunotherapy company pioneering innovative cell therapies, today announced it will share interim clinical data from its Phase 1 first-in-human study of VIPER-101, a CD5-modulated autologous CAR-T therapy for patients with relapsed or refractory (r/r) T-cell lymphoma (TCL), in a poster presentation at the American Society of Hematology

HeartCore Granted 180-Day Extension to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement

(NASDAQ:HTCR), NEW YORK and TOKYO, Nov. 10, 2025 (GLOBE NEWSWIRE) — HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or the “Company”), an IPO consulting services company based in Tokyo, announced it has received an additional 180-day extension period from the Nasdaq Listing Qualifications Department (the “Nasdaq Staff”) to regain compliance with the $1.00 minimum bid price

Vatica Health earns consistent high performer award

ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) — Vatica Health, the leader in provider-centric risk adjustment and clinical quality solutions, has earned the distinction of being named a 2025 Consistent High Performer from KLAS Research. Consistent High Performers 2025 is a new report from KLAS that identifies companies delivering exceptional client satisfaction and performance over a

Genius Group and Nuanu Complete Agreements, With a Combined Valuation of $14 Million, to Launch Genius School and Genius City, Bali

Genius Group and Nuanu Complete Agreements, With a Combined Valuation of $14 Million, to Launch Genius School and Genius City, Bali GlobeNewswire November 10, 2025 SINGAPORE, Nov. 10, 2025 (GLOBE NEWSWIRE) — Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading AI-powered, Bitcoin-first education group, today announced the completion of Share

Scroll to Top